Brelovitug (BJT-778)

Drug identity checked against registry records

Also recorded as BJT-778

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideNCT07454837MIRMPhase 2, Phase 3Recruiting2027-08-31Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.